FirstView Market Insight "Interstitial Cystitis Market Review, Epidemiology and Market Forecast2029" provides in depth understanding of historical and forecasted epidemiology along with the detailed market insights. The report covers detailed information on the disease, treatment algorithm, existing treatment and upcoming treatment regimens, unmet needs, market drivers, market barriers, sales trend and market revenue during study period 20182029.
The report also includes global forecast of epidemiology of Interstitial Cystitis from 2018 to 2029. Current studies estimate that prevalence of IC in women is 18.1 per 100,000. The joint prevalence in both sexes was 10.6 cases per 100,000. The annual incidence of new female cases is 1.2 per 100,000. Severe cases accounted for 10% of the total, and 10% of cases were in men. The femaletomale ratio for each estimate is 5:1. In United States around 2.7% to 6.5% of women have symptoms consistent with a diagnosis of interstitial cystitis/bladder pain syndrome IC/BPS.
According to research, the Interstitial Cystitis market for 7MM is estimated to be USD 427.2 Million by 2023. The number of Incident Probable IC cases is expected to reach 197,086 cases in 2023.
Report coverage:
Interstitial Cystitis Overview
This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines for Interstitial Cystitis.
Interstitial Cystitis Epidemiology Forecast
This section encompasses information on the incidence and prevalence of disease in EU5, US Japan. It also provides historical, current and forecasted estimates of diagnosed/treatable patient population.
Interstitial Cystitis Existing and Upcoming Treatment Landscape
Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning, regulatory milestones and patent exclusivity. It gives insight into the potential therapeutic targets for drug development. The section also covers major events and latest happenings, deals and collaborations.
The treatment landscape of Interstitial Cystitis can be divided into two categories based on route of administration; oral drug delivery ODD and intravesical drug delivery IDD. As of now, Elmiron Pentosan polysulfate sodium; Janssen Pharmaceuticals is the only oral delivery drug is approved by the US Food and Drug Adminstartion FDA. Major upcoming therapies such as Mirabegron Astellas Pharma; ASP 6294 Astellas Pharma; LP08 Lipella Pharmaceuticals are expected to launch during 20202027.
Interstitial Cystitis Market Size
This section of report will address the major issues, on the size and total addressable market share for Interstitial Cystitis. This will help the companies to understand and visualize their business prospects and make major decisions based on the historical, current and forecasted market share across the globe. Analyse the commercial potential of the product as well as the disease/therapy area.
Interstitial Cystitis Market Trends Unmet needs
This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.
Unmet need for noninvasive biomarkers of IC/PBS, which can enable the expedited diagnosis and advance the mechanistic understanding of IC/PBS.
Unmet need for imaging technique which will differentiate ulcerative Painful Bladder Syndrome/Interstitial Cystitis PBS/IC from nonulcerative PBS/IC.